Study on the mechanism of BGN in progression and metastasis of ccRCC.

Publisher: BioMed Central Country of Publication: England NLM ID: 101319628 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-8794 (Electronic) Linking ISSN: 17558794 NLM ISO Abbreviation: BMC Med Genomics Subsets: MEDLINE

Original Publication: London : BioMed Central

Kidney Neoplasms*/pathology ; Kidney Neoplasms*/genetics ; Cell Proliferation* ; Disease Progression* ; Carcinoma, Renal Cell*/pathology ; Carcinoma, Renal Cell*/genetics ; Carcinoma, Renal Cell*/metabolism ; Cell Movement* ; Neoplasm Metastasis* ; Biglycan*/metabolism ; Biglycan*/genetics; Humans ; Female ; Male ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Middle Aged ; MAP Kinase Signaling System

Competing Interests: Declarations. Ethics approval and consent to participate: This study is in approval with the Ethics Committee of the Affiliated Hospital of Qingdao University(approval number: QYFYWZLL26556). The patients have read and signed the informed consent form to participate. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests.
Purpose: To investigate the role of Biglycan(BGN) in the progression and metastasis of clear cell renal cell carcinoma(ccRCC).
Methods: Based on multiple public databases, we investigated the expression level of BGN in ccRCC, its clinical significance, and its association with immune cells. Real-time fluorescence quantitative polymerase chain reaction(PCR) was employed to validate BGN expression in tumor and adjacent normal tissues from ten patients. We utilized RNA sequencing results for further analysis, including differential gene analysis, GO-KEGG analysis, and GSEA analysis, to identify the signaling pathways through which BGN exerts its effects. BGN knockdown cells(786-0 and Caki-1) were generated through lentiviral transfection to examine the impact of BGN on ccRCC. Cell proliferation, migration, and invasion were assessed using CCK8, colony formation, wound healing, Transwell migration, and invasion assays, respectively.
Results: Our findings from database analysis and PCR revealed a significant upregulation of BGN expression in kidney cancer tissues compared to normal tissues. Further analysis demonstrated a correlation between high BGN expression and ccRCC progression and immune infiltration. In vitro experiments confirmed that BGN silencing effectively inhibited cell proliferation, migration, and invasion of ccRCC. Mechanistically, these effects may be mediated through the MAPK signaling pathway.
Conclusion: BGN potentially plays a pivotal role in the progression and metastasis of ccRCC, possibly acting through the MAPK signaling pathway. Therefore, BGN holds promise as a potential therapeutic target for ccRCC.
(© 2025. The Author(s).)

J Natl Compr Canc Netw. 2022 Jan;20(1):71-90. (PMID: 34991070)
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158545. (PMID: 31672572)
Nat Rev Dis Primers. 2017 Mar 09;3:17009. (PMID: 28276433)
Oncoimmunology. 2022 Jan 3;11(1):2020984. (PMID: 35003899)
Clin Transl Med. 2022 Nov;12(11):e973. (PMID: 36377223)
Curr Opin Lipidol. 2008 Oct;19(5):448-54. (PMID: 18769225)
J Mass Spectrom. 2023 Mar;58(3):e4908. (PMID: 36799777)
Front Physiol. 2023 Feb 16;14:1119368. (PMID: 36875017)
Onco Targets Ther. 2021 Mar 30;14:2279-2291. (PMID: 33833526)
Cancer Sci. 2017 Oct;108(10):1921-1926. (PMID: 28763139)
J Clin Invest. 2005 Aug;115(8):2223-33. (PMID: 16025156)
Int J Biol Sci. 2023 Jan 1;19(2):465-483. (PMID: 36632455)
Cell Death Dis. 2020 Feb 18;11(2):126. (PMID: 32071301)
Matrix Biol. 2021 Jun;100-101:150-161. (PMID: 34118408)
Proteomics. 2016 Apr;16(8):1266-70. (PMID: 26748468)
N Engl J Med. 1986 Dec 25;315(26):1650-9. (PMID: 3537791)
Oncotarget. 2014 Apr 15;5(7):1885-96. (PMID: 24681892)
Front Oncol. 2022 Jan 11;11:761030. (PMID: 35096572)
Mol Cell Biochem. 2018 Dec;449(1-2):285-294. (PMID: 29761248)
Cells. 2020 Feb 09;9(2):. (PMID: 32050430)
Int J Mol Sci. 2023 Apr 27;24(9):. (PMID: 37175653)
Chin Med J (Engl). 2022 Feb 9;135(5):584-590. (PMID: 35143424)
Nat Rev Cancer. 2009 Aug;9(8):537-49. (PMID: 19629069)
J Cell Physiol. 2020 Jan;235(1):454-464. (PMID: 31264215)
J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117323. (PMID: 37852337)
G Ital Nefrol. 2022 Jun 20;39(3):. (PMID: 35819037)
Clin Chim Acta. 2019 Apr;491:1-7. (PMID: 30629950)
Cancer Innov. 2023 Feb 24;2(1):18-24. (PMID: 38090371)
Mol Cell Biochem. 2021 Nov;476(11):3935-3950. (PMID: 34181183)
Methods Mol Biol. 2023;2619:109-124. (PMID: 36662466)
J Clin Oncol. 2022 Sep 1;40(25):2957-2995. (PMID: 35728020)
Environ Toxicol. 2023 Dec;38(12):2857-2866. (PMID: 37661780)
Cells. 2020 Apr 02;9(4):. (PMID: 32252279)
Cancer Innov. 2024 Jan 07;3(1):e105. (PMID: 38948537)
Mol Cancer. 2018 Sep 21;17(1):139. (PMID: 30241526)

82200759 National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Keywords: Biglycan; Bioinformatics; Cell migration; Cell proliferation; Clear cell renal cell carcinoma; Prognosis biomarker

0 (Biglycan)

Date Created: 20250320 Date Completed: 20250320 Latest Revision: 20250322

20250324

PMC11924620

10.1186/s12920-025-02124-5

40108593